15 August, 2007 Company Announcement Supply and Pricing of Ropren outside Russia The Directors of Solagran Limited are pleased to provide an update regarding the supply and pricing of Ropren outside Russia. Since the full results of the Ropren liver disease clinical trials were presented to 2,500 clinicians and researchers at an international gastroenterology conference in St Petersburg in May, and particularly since Ropren received final regulatory approval from the Russian Ministry of Health in July, Solagran and its manufacturing partner in St Petersburg have received a steady stream of enquiries regarding the availability of Ropren for patients with cirrhosis and other serious liver diseases living in the UK, Western Europe, Scandinavia, North America and Asia. There have also been many enquiries from doctors in the former Soviet Republics (CIS countries). In response to these requests, our manufacturing partner has decided to put in place the necessary administrative procedures to enable them to provide Ropren to patients outside Russia consistent with the specific “compassionate use” and “personal supply” provisions that exist within the regulatory frameworks of each country. As part of that decision making process, it was necessary for them to consult with Solagran to set a price for the supply of Ropren to patients outside Russia who requested supply under the appropriate regulatory provisions. Solagran has agreed to a price in the range 3,500 to 6,000 US Dollars per three month course. Solagran has independently confirmed that this price compares very favourably with other therapies currently used to treat serious liver diseases. The pricing of Ropren in Russia will be resolved with the Russian Ministry of Health in conjunction with the granting of a manufacturing licence. This is expected to occur at the latest in November. Peter Stedwell Company Secretary On behalf of the Board of Directors Solagran Limited
read that anyone thinking ropren would be selling for a few dollars a course :).........
SLA Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
